Investment
Features
FeesSafety
Academy
More
Pluang+

Compare The Magnum Ice Cream Company N.V. Ordinary Shares (MICC) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance

The Magnum Ice Cream Company N.V. Ordinary SharesTrade
Oruka Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

The Magnum Ice Cream Company N.V. Ordinary Shares vs Oruka Therapeutics Inc. Common Stock — how do they compare? The Magnum Ice Cream Company N.V. Ordinary Shares trades at $18.49 (market cap $10.72B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: The Magnum Ice Cream Company N.V. Ordinary Shares is far larger — about 2.1× Oruka Therapeutics Inc. Common Stock's market cap, and The Magnum Ice Cream Company N.V. Ordinary Shares is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold The Magnum Ice Cream Company N.V. Ordinary Shares for 0 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.

MICCORKA
Market Cap
$10.72B$5.18B
Volume
1,309,650490,798
Sector
Consumer StaplesHealth
52-Week High
$20.42$113.08
52-Week Low
$13.06$26.19
Typical Hold Time
0 Days0 Days
Enterprise Value
$14.14B$4.31B

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MICC
100% Buy0% Sell
Avg holding period · 0 Days
ORKA
100% Buy0% Sell
Avg holding period · 0 Days

About The Magnum Ice Cream Company N.V. Ordinary Shares

The Magnum Ice Cream Company N.V. manufactures and sells ice cream and frozen desserts through brands including Magnum, Ben & Jerry's, Wall's, and Cornetto, distributing across roughly 80 countries.

Read more on MICC →

About Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.

Read more on ORKA →